Jeffrey M. Leiden - Jan 8, 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Jan 8, 2024
Transactions value $
-$2,785,977
Form type
4
Date filed
1/10/2024, 04:06 PM
Previous filing
Dec 15, 2023
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$2.79M -6.65K -73.29% $419.07 2.42K Jan 8, 2024 Direct F1, F2, F3
holding VRTX Common Stock 440 Jan 8, 2024 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.
F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $419.07 (range $419.00 to $419.21).